References
- Rindi G, Leiter A, Kopin A, et al. The “normal” endocrine cell of the gut: changing concepts and new evidences. Ann N Y Acad Sci. 2004;1014:1–12.
- Bosman FT, Carneiro F, Hruban RH, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon (France): International Agency for Research on Cancer; 2010.
- Turaga K, Kvols L. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2011;61:113–132.
- Halperin DM, Shen C, Dasari A, et al. The frequency of carcinoid syndrome at neuroendocrine tumor diagnosis: a large population-based study using SEER-Medicare data. Lancet Oncol. 2017;18:525–534.
- Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342.
- Yao J, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072.
- Hallgrimsson JG, Jonsson T, Johannsson JH. Carcinoid tumors in Iceland 1955–1984: an overview and review of carcinoid tumors of the gastrointestinal tract excluding the appendix. Laeknabladid. 1989;75:201–208.
- Fraenkel M, Kim M, Faggiano A, et al. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Rel Cancer. 2014;21:R153–R163.
- Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40:1–18, vii.
- Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959.
- Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589–597.
- Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655–2664.
- Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001;92:2204–2210.
- Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105:2563–2569.
- Levi F, Te VC, Randimbison L, et al. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974–97. Br J Cancer. 2000;83:952–955.
- Lepage C, Bouvier AM, Phelip JM, et al. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut. 2004;53:549–553.
- Alsidawi S, Westin GFM, Hobday TJ, et al. Pancreatic neuroendocrine tumors: a population-based analysis of epidemiology and outcomes. JCO. 2017;35:401.
- Sigurdardottir L, Jonasson J, Stefansdottir S, et al. Data quality at the Icelandic Cancer Registry: comparability, validity, timeliness and completeness. Acta Oncol. 2012;51:880–889.
- Caldarella A, Crocetti E, Paci E. Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry. Pathol Oncol Res. 2011;17:759–763.
- Westergaard T, Frisch M, Melbye M. Carcinoid tumors in Denmark 1978–1989 and the risk of subsequent cancers. A population-based study. Cancer. 1995;76:106–109.
- Quaedvlieg PFHJ, Visser O, Lamers CBHW, et al. Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2391 patients. Ann Oncol. 2001;12:1295–1300.
- Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, et al. Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010. Neuroendocrinology. 2017;104:1–10.
- Sundaresan S, Kang AJ, Merchant JL. Pathophysiology of gastric NETs: role of gastrin and menin. Curr Gastroenterol Rep. 2017;19:32.
- Helgadottir H, Metz DC, Yang YX, et al. The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin. Dig Liver Dis. 2014;46:125–130.